Systemic IFN-α drives kidney nephritis in B6.Sle123 mice

European Journal of Immunology

Volumn 38, Issue 7, 2008, Pages 1948-1960

  Fairhurst, Anna Marie ^a   Mathian, Alexis ^c   Connolly, John E ^d   Wang, Andrew ^a   Gray, Hillery F ^a   George, Tiffany A ^a   Boudreaux, Christopher D ^a   Zhou, Xin J ^b   Li, Quan Zhen ^e   Koutouzov, Sophie ^e   Banchereau, Jacques ^d   Wakeland, Edward K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^e INSERM   (France)

Author keywords

Congenic; IFN; Systemic lupus erythematosus

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; B6 SLE123 MOUSE; BONE MARROW; C57BL 6 MOUSE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPOSITION; CELL DIFFERENTIATION; CELL LINEAGE; CELL LOSS; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; EXPERIMENTAL MOUSE; EXPRESSION VECTOR; FEMALE; GENE CASSETTE; IMMUNOGLOBULIN DEPOSITION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; PLASMA CELL; PRIORITY JOURNAL; SPLENOMEGALY; ANIMAL; ANTIGEN ANTIBODY COMPLEX; BONE MARROW CELL; CYTOLOGY; GENE VECTOR; GLOMERULONEPHRITIS; IMMUNOLOGY; KIDNEY; METABOLISM; PATHOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; B-LYMPHOCYTES; DENDRITIC CELLS; GENETIC VECTORS; GLOMERULONEPHRITIS; INTERFERON-ALPHA; KIDNEY; LEUKOPENIA; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MICE; MYELOID CELLS; SPLENOMEGALY; T-LYMPHOCYTES;

EID: 50549103097     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200837925     Document Type: Article

References (57)

1. Wakeland, E. K., Liu, K., Graham, R. R. and Behrens, T. W., Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001. 15: 397-408.
2. Vyse, T. J. and Kotzin, B. L., Genetic susceptibility to systemic lupus erythematosus. Annu. Rev. Immunol. 1998. 16: 261-292.
3. Harley, J. B., Moser, K. L., Gaffney, P.M. and Behrens, T.W., The genetics of human systemic lupus erythematosus. Curr. Opin. Immunol. 1998. 10: 690-696.
4. Marrack, P., Kappler, J. and Kotzin, B. L., Autoimmune disease: Why and where it occurs. Nat. Med. 2001. 7: 899-905.
5. Lipsky, P. E., Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity. Nat. Immunol. 2001. 2: 764-766.
6. Desai-Mehta, A., Lu, L., Ramsey-Goldman, R. and Datta, S. K., Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. 1996. 97: 2063-2073.
7. Wandl, U. B., Nagel-Hiemke, M., May, D., Kreuzfelder, E., Kloke, O., Kranzhoff, M., Seeber, S. and Niederle, N., Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin. Immunol. Immunopathol. 1992. 65: 70-74.
8. Vallin, H., Perers, A., Alm, G. V. and Ronnblom, L., Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J. Immunol. 1999. 163: 6306-6313.
9. Vallin, H., Blomberg, S., Alm, G. V., Cederblad, B. and Ronnblom, L., Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin. Exp. Immunol. 1999. 115: 196-202.
10. Schilling, P. J., Kurzrock, R., Kantarjian, H., Gutterman, J. U. and Talpaz, M., Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991. 68: 1536-1537.
11. Ronnblom, L. E., Alm, G. V. and Oberg, K. E., Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 1991. 115: 178-183.
12. Preble, O. T., Rothko, K., Klippel, J. H., Friedman, R. M. and Johnston, M. I., Interferon-induced 20-50 adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J. Exp. Med. 1983. 157: 2140-2146.
13. Dall'era, M. C., Cardarelli, P. M., Preston, B. T., Witte, A. and Davis, J. C., Jr., Type I interferon correlates with serological and clinical manifestations of SLE. Ann. Rheum. Dis. 2005. 64: 1692-1697.
14. Blanco, P., Palucka, A. K., Gill, M., Pascual, V. and Banchereau, J., Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001. 294: 1540-1543.
15. Kirou, K. A., Lee, C., George, S., Louca, K., Peterson, M. G. and Crow, M. K., Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005. 52: 1491-1503.
16. Han, G. M., Chen, S. L., Shen, N., Ye, S., Bao, C. D. and Gu, Y. Y., Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun. 2003. 4: 177-186.
17. Crow, M. K. and Wohlgemuth, J., Microarray analysis of gene expression in lupus. Arthritis Res. Ther. 2003. 5: 279-287.
18. Bennett, L., Palucka, A. K., Arce, E., Cantrell, V., Borvak, J., Banchereau, J. and Pascual, V., Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003. 197: 711-723.
19. Baechler, E. C., Batliwalla, F.M., Karypis, G., Gaffney, P.M., Ortmann, W. A., Espe, K. J., Shark, K. B. et al., Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 2003. 100: 2610-2615.
20. Santiago-Raber, M. L., Baccala, R., Haraldsson, K. M., Choubey, D., Stewart, T. A., Kono, D. H. and Theofilopoulos, A. N., Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 2003. 197: 777-788.
21. Hron, J. D. and Peng, S. L., Type I IFN protects against murine lupus. J. Immunol. 2004. 173: 2134-2142.
22. Braun, D., Geraldes, P. and Demengeot, J., Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J. Autoimmun. 2003. 20: 15-25.
23. Mathian, A., Weinberg, A., Gallegos, M., Banchereau, J. and Koutouzov, S., IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J. Immunol. 2005. 174: 2499-2506.
24. Morel, L., Rudofsky, U. H., Longmate, J. A., Schiffenbauer, J. and Wakeland, E. K., Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994. 1: 219-229.
25. Morel, L., Yu, Y., Blenman, K. R., Caldwell, R. A. and Wakeland, E. K., Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Mamm. Genome 1996. 7: 335-339.
26. Morel, L., Blenman, K. R., Croker, B. P. and Wakeland, E. K., The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc. Natl. Acad. Sci. USA 2001. 98: 1787-1792.
27. Mohan, C., Yu, Y., Morel, L., Yang, P. and Wakeland, E. K., Genetic dissection of SLE pathogenesis: Sle3 on murine chromosome 7 impacts Tcell activation, differentiation, and cell death. J. Immunol. 1999. 162: 6492-6502.
28. Mohan, C., Alas, E., Morel, L., Yang, P. and Wakeland, E. K., Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J. Clin. Invest. 1998. 101: 1362-1372.
29. Mohan, C., Morel, L., Yang, P. and Wakeland, E. K., Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity. J. Immunol. 1997. 159: 454-465.
30. Li, Q. Z., Xie, C., Wu, T., Mackay, M., Aranow, C., Putterman, C. and Mohan, C., Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J. Clin. Invest. 2005. 115: 3428-3439.
31. Loder, F., Mutschler, B., Ray, R. J., Paige, C. J., Sideras, P., Torres, R., Lamers, M. C. and Carsetti, R., B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J. Exp. Med. 1999. 190: 75-89.
32. Youinou, P., Jamin, C., Pers, J. O., Berthou, C., Saraux, A. and Renaudineau, Y., B lymphocytes are required for development and treatment of autoimmune diseases. Ann. N. Y. Acad. Sci. 2005. 1050: 19-33.
33. Han, S., Zheng, B., Schatz, D. G., Spanopoulou, E. and Kelsoe, G., Neoteny in lymphocytes: RAG1 and RAG2 expression in germinal center B cells. Science 1996. 274: 2094-2097.
34. Wang, J., Lin, Q., Langston, H. and Cooper, M. D., Resident bone marrow macrophages produce type 1 interferons that can selectively inhibit interleukin-7-driven growth of B lineage cells. Immunity 1995. 3: 475-484.
35. - thymocytes. Immunology 1997. 90: 543-549.
36. Lin, Q., Dong, C. and Cooper, M. D., Impairment of T and B cell development by treatment with a type I interferon. J. Exp. Med. 1998. 187: 79-87.
37. Taylor, P. R., Brown, G. D., Geldhof, A. B., Martinez-Pomares, L. and Gordon, S., Pattern recognition receptors and differentiation antigens define murine myeloid cell heterogeneity ex vivo. Eur. J. Immunol. 2003. 33: 2090-2097.
38. Geissmann, F., Jung, S. and Littman, D. R., Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003. 19: 71-82.
39. Brown, N. J., Hutcheson, J., Bickel, E., Scatizzi, J. C., Albee, L. D., Haines, G. K., 3rd, Eslick, J. et al., Fas death receptor signaling represses monocyte numbers and macrophage activation in vivo. J. Immunol. 2004. 173: 7584-7593.
40. Henderson, R. B., Hobbs, J. A., Mathies, M. and Hogg, N., Rapid recruitment of inflammatory monocytes is independent of neutrophil migration. Blood 2003. 102: 328-335.
41. Schlueter, A. J., Krieg, A.M., de Vries, P. and Li, X., Type I interferon is the primary regulator of inducible Ly-6C expression on T cells. J. Interferon Cytokine Res. 2001. 21: 621-629.
42. Dumont, F. J. and Coker, L. Z., Interferon-alpha/beta enhances the expression of Ly-6 antigens on T cells in vivo and in vitro. Eur. J. Immunol. 1986. 16: 735-740.
43. Shortman, K. and Liu, Y. J., Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2002. 2: 151-161.
44. + dendritic cells is restricted by post-activation death. Int. Immunol. 2006. 18: 415-423.
45. O'Keeffe, M., Grumont, R. J., Hochrein, H., Fuchsberger, M., Gugasyan, R., Vremec, D., Shortman, K. and Gerondakis, S., Distinct roles for the NF-kappaB1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals. Blood 2005. 106: 3457-3464.
46. Pawar, R. D., Patole, P. S., Zecher, D., Segerer, S., Kretzler, M., Schlondorff, D. and Anders, H. J., Toll-like receptor-7 modulates immune complex glomerulonephritis. J. Am. Soc. Nephrol. 2006. 17: 141-149.
47. Anders, H. J., Banas, B., Linde, Y., Weller, L., Cohen, C. D., Kretzler, M., Martin, S. et al., Bacterial CpG-DNA aggravates immune complex glomerulonephritis: Role of TLR9-mediated expression of chemokines and chemokine receptors. J. Am. Soc. Nephrol. 2003. 14: 317-326.
48. Anders, H. J., A Toll for lupus. Lupus 2005. 14: 417-422.
49. Patole, P. S., Grone, H. J., Segerer, S., Ciubar, R., Belemezova, E., Henger, A., Kretzler, M. et al., Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J. Am. Soc. Nephrol. 2005. 16: 1326-1338.
50. Anders, H. J., Vielhauer, V., Eis, V., Linde, Y., Kretzler, M., Perez de Lema, G., Strutz, F. et al., Activation of Toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J. 2004. 18: 534-536.
51. Jorgensen, T. N., Thurman, J., Izui, S., Falta, M. T., Metzger, T. E., Flannery, S. A., Kappler, J. et al., Genetic susceptibility to polyI:C-induced IFNalpha/beta-dependent accelerated disease in lupus-prone mice. Genes Immun. 2006. 7: 555-567.
52. Jego, G., Pascual, V., Palucka, A. K. and Banchereau, J., Dendritic cells control B cell growth and differentiation. Curr. Dir. Autoimmun. 2005. 8: 124-139.
53. Shimizu, S., Nakashima, H., Masutani, K., Inoue, Y., Miyake, K., Akahoshi, M., Tanaka, Y. et al., Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford) 2004. 43: 1121-1128.
54. Inoue, A., Hasegawa, H., Kohno, M., Ito, M. R., Terada, M., Imai, T., Yoshie, O. et al., Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/ lprmice. Arthritis Rheum. 2005. 52: 1522-1533.
55. Morel, L., Croker, B. P., Blenman, K. R., Mohan, C., Huang, G., Gilkeson, G. and Wakeland, E. K., Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc. Natl. Acad. Sci. USA 2000. 97: 6670-6675.
56. Xie, C., Zhou, X. J., Liu, X. and Mohan, C., Enhanced susceptibility to endorgan disease in the lupus-facilitating NZW mouse strain. Arthritis Rheum. 2003. 48: 1080-1092.
57. Mohan, C., Morel, L., Yang, P., Watanabe, H., Croker, B., Gilkeson, G. and Wakeland, E. K., Genetic dissection of lupus pathogenesis: A recipe for nephrophilic autoantibodies. J. Clin. Invest. 1999. 103: 1685-1695.